From Brain to Behavior: Mechanistic and Therapeutic Insights into Mood and Anxiety Disorders

Among the most common neuropsychiatric conditions, depression and anxiety impact millions of people worldwide and present serious public health issues. These disorders cause significant emotional, cognitive, and functional impairments due to intricate interplay between neurobiological, psychosocial, and environmental variables. With an emphasis on their neuropsychological foundations, this study offers a thorough examination of both established and novel therapy approaches for treating anxiety and depression. For many individuals, traditional pharmaceutical treatments including benzodiazepines, serotonin-norepinephrine reuptake inhibitors, and selective serotonin reuptake inhibitors continue to be the first choice. Nevertheless, these treatments frequently have drawbacks because of their partial response, delayed commencement of action, and adverse effects. Consequently, non-pharmacological and neuromodulator methods such as transcranial magnetic stimulation, electroconvulsive treatment, mindfulness-based interventions, and cognitive-behavioural therapy are gaining popularity. Ketamine, esketamine, and psychedelic-assisted therapies are examples of new medicines that have been developed recently and give quick and potentially life-changing results in situations that are resistant to previous treatments. Research on neuroinflammation, the gut-brain axis, and personalized medicine has also created new avenues for tailored treatment. There is potential for better results when various therapy methods that are customized for each patient’s neurobiological profile are integrated. The significance of a multimodal treatment strategy that incorporates pharmaceutical, psychological, and developing therapies is emphasized by this review. In order to maximize the effectiveness of treatment and get a deeper understanding of the mechanisms behind these diseases, it also emphasizes the necessity of further study.